Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Myelodysplastic Syndromes 26Recurrence 18Multiple Myeloma 18Lymphoma, Non-Hodgkin 15Lymphoma, B-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma 14Ovarian Neoplasms 12Hematologic Neoplasms 12Pancreatic Neoplasms 10Melanoma 10Hodgkin Disease 10Myeloproliferative Disorders 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 9Burkitt Lymphoma 9Stomach Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Neoplasms 7Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Leukemia, Biphenotypic, Acute 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Breast Neoplasms 6

Interventions

liposomal doxorubicin 1fludarabine 1dostarlimab 1Paclitaxel 1Nivolumab 1Ipilimumab 1Gemcitabine 1Doxorubicin 1Dexamethasone 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × fludarabine × 90 days × Clear all
NCT07072234 2026-04-29

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 1 Recruiting
30 enrolled

Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡